
Angelique Gougelet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1180054/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. Journal of Clinical Investigation, 2012, 122, 586-599.	8.2	155
2	Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor α (ERα), Differentially Affect ERα Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells. Molecular Endocrinology, 2003, 17, 2013-2027.	3.7	138
3	T-cell factor 4 and β-catenin chromatin occupancies pattern zonal liver metabolism in mice. Hepatology, 2014, 59, 2344-2357.	7.3	137
4	Microâ€RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. International Journal of Cancer, 2011, 129, 680-690.	5.1	129
5	β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut, 2019, 68, 322-334.	12.1	94
6	Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut, 2016, 65, 1024-1034.	12.1	61
7	Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 111-121.	2.5	49
8	Estrogen receptor α and β subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 71-81.	2.5	46
9	Oestrogen receptors pathways to oestrogen responsive elements: The transactivation function-1 acts as the keystone of oestrogen receptor (ER)β-mediated transcriptional repression of ERα. Journal of Steroid Biochemistry and Molecular Biology, 2007, 104, 110-122.	2.5	46
10	Expression of NKG2D ligands is downregulated by \hat{I}^2 -catenin signalling and associates with HCC aggressiveness. Journal of Hepatology, 2021, 74, 1386-1397.	3.7	37
11	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology, 2019, 157, 807-822.	1.3	22
12	A Complex Interplay between Wnt/ <i>β</i> -Catenin Signalling and the Cell Cycle in the Adult Liver. International Journal of Hepatology, 2012, 2012, 1-7.	1.1	21
13	Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Anti–IL-6 Antibody. PLoS ONE, 2009, 4, e8026.	2.5	19
14	Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. Journal of Hepatology, 2022, 77, 424-435.	3.7	17
15	miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. Sarcoma, 2011, 2011, 1-13.	1.3	15
16	Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. World Journal of Hepatology, 2018, 10, 785-789.	2.0	13
17	MicroRNA-feedback loop as a key modulator of liver tumorigenesis and inflammation. World Journal of Gastroenterology, 2013, 19, 440.	3.3	10
18	Hepatocellular carcinoma diagnosis: Circulating microRNAs emerge as robust biomarkers. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 367-369.	1.5	9

ANGELIQUE GOUGELET

#	Article	IF	CITATIONS
19	Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions?. Gut, 2016, 65, 1073-1074.	12.1	7
20	Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology, 2021, 13, 979-1002.	2.0	5
21	Non-coding RNAs open a new chapter in liver cancer treatment. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 630-637.	1.5	3
22	The concomitant loss of <scp>APC</scp> and <scp>HNF</scp> 4α in adult hepatocytes does not contribute to hepatocarcinogenesis driven by β atenin activation. Liver International, 2019, 39, 727-739.	3.9	3
23	MicroRNAs Linking Cancer and Inflammation: Focus on Liver Cancer. , 2014, , 183-208.		3
24	ARID1A loss in adult hepatocytes activates β-catenin-mediated erythropoietin transcription. ELife, 2020, 9, .	6.0	3
25	Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma?. Gut, 2019, 68, 1727-1728.	12.1	2
26	Upregulation of the imprinted DLK1/DIO3 locus in response to beta-catenin activation: a promising target for HCC treatment. Journal of Hepatology, 2018, 68, S94-S95.	3.7	0
27	Noncoding RNAs in liver cancer patients. , 2022, , 343-389.		0